MET and non-small cell lung carcinoma: Another phase 3 trial of the c‐Met inhibitor tivantinib in Asian patients with previously treated EGFR‐wildtype NSCLC found potential antitumor activity, but the trial was prematurely terminated due to an increased incidence of interstitial lung disease in the tivantinib arm.23